A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

This Phase II trial is testing tebentafusp, an immunotherapy drug, in patients with advanced clear cell sarcoma — a rare soft tissue cancer — who carry a specific immune marker called HLA-A*02:01. **You may be eligible if...** - You are 18 or older - You have confirmed unresectable or metastatic clear cell sarcoma (a type of soft tissue cancer) - You test positive for HLA-A*02:01 (a specific genetic immune marker) - You have measurable disease on CT or MRI scans - Your performance status is ECOG 2 or better - Your organ function (blood counts, liver, kidney) meets the required levels **You may NOT be eligible if...** - Your tumor is HLA-A*02:01-negative - Your cancer is not the clear cell sarcoma subtype - You have severe organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.